TITLE

Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR

AUTHOR(S)
Milla, Carlos E.; Ratjen, Felix; Marigowda, Gautham; Fang Liu; Waltz, David; Rosenfeld, Margaret; Liu, Fang; VX13-809-011 Part B Investigator Group *
PUB. DATE
April 2017
SOURCE
American Journal of Respiratory & Critical Care Medicine;4/1/2017, Vol. 195 Issue 7, p912
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Rationale: Combination lumacaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for F508del-CFTR, but it has not been assessed in younger patients.Objectives: In this open-label phase III trial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaftor/ivacaftor combination therapy in patients aged 6-11 years with cystic fibrosis who were homozygous for F508del-CFTR.Methods: Patients (N = 58) received 200 mg lumacaftor/250 mg ivacaftor orally every 12 hours for 24 weeks in addition to their existing cystic fibrosis medications.Measurements and Main Results: Lumacaftor/ivacaftor was well tolerated; the safety profile was generally similar to that observed in larger lumacaftor/ivacaftor trials with older patients. Four patients discontinued (two because of drug-related adverse events: elevated liver transaminases, n = 1; rash, n = 1). No safety concerns were associated with spirometry. No significant changes in percent predicted FEV1 were observed (change from baseline at Week 24, +2.5 percentage points; 95% confidence interval [CI], -0.2 to 5.2; P = 0.0671). At Week 24, significant improvements from baseline were observed in sweat chloride (-24.8 mmol/L; 95% CI, -29.1 to -20.5; P < 0.0001), body mass index z score (+0.15; 95% CI, 0.08 to 0.22; P < 0.0001), Cystic Fibrosis Questionnaire-Revised respiratory domain score (+5.4; 95% CI, 1.4 to 9.4; P = 0.0085), and lung clearance index based on lung volume turnover required to reach 2.5% of starting N2 concentration (-0.88; 95% CI, -1.40 to -0.37; P = 0.0018).Conclusions: Lumacaftor/ivacaftor was well tolerated in this young population; no new safety concerns were identified. Improvements in lung clearance index, sweat chloride, nutritional status, and health-related quality of life were observed after 24 weeks of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT01897233).
ACCESSION #
122464772

 

Related Articles

  • Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. Roche, Nicolas; Chapman, Kenneth R.; Vogelmeier, Claus F.; Herth, Felix J. F.; Chau Thach; Fogel, Robert; Olsson, Petter; Patalano, Francesco; Banerji, Donald; Wedzicha, Jadwiga A.; Thach, Chau // American Journal of Respiratory & Critical Care Medicine;5/1/2017, Vol. 195 Issue 9, p1189 

    Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).Objectives: We prospectively investigated the value of blood...

  • Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis. Morgan, Wayne J.; Wagener, Jeffrey S.; Pasta, David J.; Millar, Stefanie J.; VanDevanter, Donald R.; Konstan, Michael W.; Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis // Annals of the American Thoracic Society;Jun2017, Vol. 14 Issue 6, p937 

    Rationale: Children with cystic fibrosis often experience acute declines in lung function. We previously showed that such declines are not always treated with antibiotics, but we did not assess whether treatment improves the likelihood of recovery.Objectives: To...

  • Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. Stanojevic, Sanja; Davis, Stephanie D.; Retsch-Bogart, George; Webster, Hailey; Davis, Miriam; Johnson, Robin C.; Jensen, Renee; Pizarro, Maria Ester; Kane, Mica; Clem, Charles C.; Schornick, Leah; Subbarao, Padmaja; Ratjen, Felix A. // American Journal of Respiratory & Critical Care Medicine;5/1/2017, Vol. 195 Issue 9, p1216 

    Rationale: Implementation of intervention strategies to prevent lung damage in early cystic fibrosis (CF) requires objective outcome measures that capture and track lung disease.Objectives: To define the utility of the Lung Clearance Index (LCI), measured by multiple...

  • A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis. Calvin Lu; Hye-Seung Lee; Pappas, George P.; Dilling, Daniel F.; Burger, Charles D.; Shifren, Adrian; Veeraraghavan, Srihari; Chapman, Jeffrey T.; Parambil, Joseph; Ruoss, Stephen J.; Young, Lisa R.; Hammes, Stephen R.; Kopras, Elizabeth J.; Roads, Tammy; Krischer, Jeffrey P.; McCormack, Francis X.; Lu, Calvin; Lee, Hye-Seung; Trial of an Aromatase Inhibitor in Lymphangioleiomyomatosis Group // Annals of the American Thoracic Society;Jun2017, Vol. 14 Issue 6, p919 

    Rationale: Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease that predominantly affects women and can worsen with pregnancy, estrogen treatment, and the menstrual cycle, suggesting an important role for estrogen in disease pathogenesis.Objectives: To...

  • Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Kahramanoğlu Aksoy, Evrim; Pirinçci Sapmaz, Ferdane; Göktaş, Zeynep; Uzman, Metin; Nazlıgül, Yaşar; Kahramanoğlu Aksoy, Evrim; Pirinçci Sapmaz, Ferdane; Göktaş, Zeynep; Nazlıgül, Yaşar // Medical Principles & Practice;Feb2018, Vol. 26 Issue 6, p523 

    Objective: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth-containing quadruple therapy as a first-line regimen for the eradication of Helicobacter...

  • Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. Cheng, Guang-Shing; Storer, Barry; Chien, Jason W; Jagasia, Madan; Hubbard, Jesse J; Burns, Linda; Ho, Vincent T; Pidala, Joseph; Palmer, Jeanne; Johnston, Laura; Mayer, Sebastian; Crothers, Kristina; Pusic, Iskra; Lee, Stephanie J; Williams, Kirsten M // Annals of the American Thoracic Society;Nov2016, Vol. 13 Issue 11, p1932 

    Rationale: The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly characterized. Understanding the trajectory of lung function is necessary for prompt clinical recognition and treatment...

  • Effect of Continuous Positive Airway Pressure on Airway Reactivity in Asthma. A Randomized, Sham-controlled Clinical Trial. Holbrook, Janet T.; Sugar, Elizabeth A.; Brown, Robert H.; Drye, Lea T.; Irvin, Charles G.; Schwartz, Alan R.; Tepper, Robert S.; Wise, Robert A.; Yasin, Razan Z.; Busk, Michael F.; American Lung Association Airways Clinical Research Centers // Annals of the American Thoracic Society;Nov2016, Vol. 13 Issue 11, p1940 

    Rationale: Studies have demonstrated that application of stress suppresses airway smooth muscle contractility. In animal models of asthma, continuous positive airway pressure (CPAP) reduced airway reactivity. Short-term studies of CPAP in patients with asthma showed reductions in...

  • Ivacaftor: A new emerging treatment option in the management of cystic fibrosis. Song, Jessica C.; Chiu, Hilda; Yoon, Jennefer // Formulary;Apr2012, Vol. 47 Issue 4, p132 

    Ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, has been approved by FDA for treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation in the CFTR gene. This agent offers a novel approach to the treatment of cystic fibrosis,...

  • Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. GÙell, Maria-Rosa; Cejudo, Pilar; Ortega, Francisco; Puy, M. Carmen; Rodríguez-Trigo, Gema; Pijoan, José Ignacio; Martinez-Indart, Lorea; Gorostiza, Amaia; Bdeir, Khaled; Celli, Bartolome; Galdiz, Juan B.; Güell, Maria-Rosa // American Journal of Respiratory & Critical Care Medicine;3/1/2017, Vol. 195 Issue 5, p622 

    Rationale: In chronic obstructive pulmonary disease (COPD), the benefits of pulmonary rehabilitation (PR) tend to wane over time. Whether maintenance techniques may help sustain the benefits achieved after completion of the initial PR program remains controversial.Objectives:...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics